Japan's Global Health Initiative Technology Fund is investing $15.3 million to speed the development of new drugs and vaccines for malaria, dengue and Chagas disease.
Still suffering from the loss of patent protection on its big Alzheimer's drug Aricept, Japan's Eisai said today that the company had fired off a pair of applications for its new cancer drug to U.S. as well as European regulators.
With M&A deals percolating around the global biopharma industry, investors bought in to the story anyway, driving up Chugai's stock price to record levels on the market buzz as fresh press reports added to the speculative frenzy.
Lombard Medical scored Japanese regulatory approval for its endovascular stent graft system, moving the company forward in its quest to grab a bigger piece of the endovascular aneurysm repair market.
One of the authors of a controversial and now-retracted paper purporting a stem cell breakthrough has been found dead in what appears to be a suicide, according to numerous reports, following an investigation that has alarmed researchers and rattled one of Japan's most respected institutions.
Facing its second scandal in as many months, Novartis' Japanese unit has issued an apology for failing to disclose side effects of its drugs Tasigna and Gleevec, which are used to treat leukemia.
In a deal that will build on their existing mutual relationship, Bristol-Myers Squibb and Ono Pharmaceutical have formed a pact to bring immunotherapies to market in Japan, South Korea and Taiwan.
Contract developer Catalent is planning to open a new facility in Japan as it marks 40 years doing business in the country, looking to expand its scale in R&D and manufacturing.
Intuitive Surgical is kicking off direct sales of its da Vinci Surgical Systems in Japan, continuing its push in emerging markets and hoping to generate positive numbers after a year of sluggish sales.
Last month, Japanese authorities arrested an ex-Novartis employee who allegedly manipulated trial data later used to promote the blockbuster blood pressure med Diovan. But now, it looks as if he may not be the only one paying the price.